Vimarsana
Biggest News Aggregation in the World

Page 48 - Jonathan Schott News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Jonathan Schott. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Jonathan Schott Today - Breaking & Trending Today

'Fascinating' Link Between Alzheimer's and COVID-19 - Vimarsana News

'Fascinating' Link Between Alzheimer's and COVID-19

Alzheimer's risk and susceptibility to severe COVID-19 share a common genetic mechanism; the new findings that could lead to novel treatments to slow progression and severity of both diseases.

Gene that increases risk of Alzheimer's 'also raises chance of severe Covid' - Vimarsana News

Gene that increases risk of Alzheimer's 'also raises chance of severe Covid'

New research suggests underlying genetics may explain why coronavirus was so deadly in care homes throughout the pandemic

Potential cognitive benefits of major Alzheimer's risk gene - Vimarsana News

Potential cognitive benefits of major Alzheimer's risk gene

A well-known gene that increases Alzheimer’s risk, called APOE4, has now been linked with better visual working memory in older adults, finds a new

Santé. Alzheimer, un nouvel espoir en demi-teinte - Vimarsana News

Santé. Alzheimer, un nouvel espoir en demi-teinte

 Décryptage Vingt ans que la recherche patine contre Alzheimer, et vingt ans qu’à intervalles réguliers des annonces promettent une « réelle avancée » contre ce fléau qui empoisonne la fin de vie de 50 millions de personnes dans le monde (150 millions d’ici à 2050), dont plus de 900 000 en France. Le 7 juin dernier, nouveau rebondissement : l’agence américaine du médicament, la puissante Food and Drug Administration (FDA), indique avoir autorisé une molécule, l’aducanumab, produite par l’entreprise Biogen, sous le nom commercial d’Aduhelm. « Il s’agit...

America's wary approval of an Alzheimer's drug offers hope to millions - Vimarsana News

America's wary approval of an Alzheimer's drug offers hope to millions

But its makers still have work to do to prove it can slow the advance of dementia | Science & technology